Best Of ASCO, Ciudad de México 2014

La Sociedad Americana de Oncología Clínica, American Society of Clinical Oncology (ASCO), ha seleccionado a nuestra ciudad, para la realización del evento de difusión científica: Best of ASCO (BOA) Ciudad de México 2014 segunda edición, que se llevará a cabo el 19 y 20 de Junio del 2014, donde se presentarán los últimos avances en Oncología y los más relevantes trabajos expuestos en su reunión anual ASCO 2014.

Best of ASCO Ciudad de México 2014 segunda edición, con enfoque en divulgación de programas de educación médica continua en nuestro país. Este evento será organizado por Medical Pharma Research LATAM LLC, bajo un acuerdo de divulgación científica con The American Society of Clinical Oncology (ASCO), el aval Académico y respaldo de las más importantes instituciones nacionales enfocadas al tratamiento del cáncer.

El evento cuenta con 5 puntos curriculares para recertificación médica y tendremos en el aparador los connotados médicos de la oncología de habla hispana.

JUEVES 19 DE JUNIO

Comité Científico Dra. Erazo/ Dr. De la Garza/ Dra. Torrecillas/ Dr. Farias.

09:00 Inauguración

BREAST

Coordinador Dr. Silva CMN Siglo XXI

09:15 Phatological complete response rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triplenegative breast cancer: Results from GeparSIxto.

09:30 Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatinbased chemotherapy.

09:45 Mesa Redonda Ponentes y Coordinadores.

BREAST HER 2

Coordinador Dr. Aguilar INCan

10:00 First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone, trastuzumab alone, their sequence (T>L), or their combination in the adjuvant treatment of HER2-positive early breast cancer.

10:15 Bevacizumab in the adjuvant treatment of HER2- negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.

10:30 Efficacy of adjuvant trastuzumab (T) compared with no T for patients with HER2-positive breast cancer and tumors ≤2 cm: A meta-analysis of the randomized trastuzumab trials.

10:45 Mesa Redonda Ponentes y Coordinadores.

10:45 COFFEE BREAK

GYN

Coordinador Dra. G. Cervantes CMN 20 de Noviembre

11:30 A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. Ponente Dra. G. Díaz CMN 20 de Nov

11:45 Molecular subgroup of high-grade serious ovarian cancer as a predictor of outcome following bevacizumab.

12:00 Mesa Redonda Ponentes y Coordinadores.

GI

Coordinador Dr. R. Medrano CMN Siglo XXI

12:15 CALGB /SWOG 80405: Phase III Trial of irinotecan/5FU/ Leucovorin (FOLFIRI) or oxaliplatin/5FU/ Leucovorin(mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum.

12:30 Maintenance strategy with fluoropyrimidines plus Bevacizumab, Bev alone, or no treatment, following a standard combination of FP, oxaliplatin, and Bev as first-line treatment for patients with metastatic colorectal cancer: a phase III non-inferiority trial (AIO KRK 0207).

12:45 Final results and subgroups analyses of the Phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after introduction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer.

13:00 A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel (PTX) versus placebo plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma following desease progression on first-line platinum and fluoropyrimidine-containing combination therapy. Efficacy analysis in Japanese and Western patients.

13:15 Mesa Redonda Ponentes y Coordinadores.

SARCOMA

Coordinador Dr. Ochoa Carrillo INCan

13:30 Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib: 10 year outcomes from SWOG phase III intergroup trial S0033.

PATIENT AND SURVIVOR CARE

Coordinador Clemenceau Delegado en México de MASCC

13:45 Aprepitant versus Metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study.

14:00 Plática Magistral.

SIMPOSIUM

S M. Domchek MD Abramson Cancer Center

14:30 Marcadores Genéticos en Ca de Mama.

VIERNES 20 DE JUNIO

Dra. Cervantes / Dra Torrecillas

08:00 Desayuno con el Experto

Estratégias en resistencia a hormonoterapia en Cáncer de Mama

GU

Coordinador Dra. Paula Cabrera ISSEMYM

9:05 Impact on survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: An ECOG-led phase III randomized trial.

CHAARTED NIH P Oral

Ponente Dra. G. Garnica Hospital Gral. de México

Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with chemotherapynaive metastatic castration-resistant prostate cancer (ELMPC 4Trial).

Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal carcinoma ( The ESPN trial)

10:05 “Ampliando horizontes en CCRm: Maximizando los beneficios del tratamiento”.

11:05 COFFEE BREAK

HEAD & NECK

Coordinador Dr. J Robles PEMEX

11:30 Concomitant chemoradiation or cetuximab/RT versus induction Docetaxel/ Cisplatin/5-Fluoracil followed by CRT or CET/Rt in patients with locally advanced Squamous Cell Carcinoma of Head and Neck ( LASCCHN). A randomized phase III factorial study (NCT01086826).

Final Analysis: A randomized, blinded, placebo-controlled phase III study of adjuvant postoperative lapatinib with concurrent chemotherapy and radiation therapy in highrisk patients with squamous cell carcinoma of the head and neck (SCCHN).

A Phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131 I-refractory differentiated thiroid cancer ( SELECT).

Mesa Redonda Ponentes y Coordinadores.

MELANOMA

Ponente Dra. G. Alvarado H. Gea A Glez. / Dr. JA Matus INCan

12:30 COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to Dabrafenib and trametinib placebo as firstline therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.

Mesa Redonda Ponentes y Coordinadores.

LUNG

Coordinador Dr. L. León Hospital Gral. de México

13:15 First line crizotinb versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALKpositive non-squamous non-small cell lung cancer: results of a phase III study (PROFILE 1014).

REVEL: A randomized, double-blind, phase III study of docetaxel and ramucirumab (RAM; IMC-1121B) versus DOC and placebo in the second-line treatment of stage IV nonsmall cell lung cancer following disease progression after one platinum-based therapy.

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.

Mesa Redonda Ponentes y Coordinadores.

Dr. Jaime De la Garza

14:15 Historia de la Oncología Médica en México

(1967 – 2014).

Comité Científico Dra. Erazo/ Dr. De la Garza/ Dra. Torrecillas/ Dr. Farias

14:45 Clausura de Actividades.

Acerca Redacción

Equipo de redacción de la red de Mundodehoy.com, LaSalud.mx y Oncologia.mx

También te puede interesar

Cáncer de pulmón, principal causa de muerte por cáncer

Pulmón.mx.- A nivel mundial, el cáncer de pulmón es el tipo de cáncer más frecuente …

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *